Cost-Effectiveness of Nirsevimab and Clesrovimab in Preventing Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Modeling Study
Our findings predict that nirsevimab is economically dominant over clesrovimab while providing greater clinical protection against RSV-related disease in these scenarios. These results are robust to sensitivity analyses with nirsevimab consistently estimated as reducing healthcare resource utilization and total costs compared to clesrovimab across assumptions related to clesrovimab duration of cumulative efficacy as well as variation in key model parameters.
Authors
- Samira Soudani (ORCID: https://orcid.org/0009-0006-4523-6588)
- Erin N. Hodges (ORCID: https://orcid.org/0000-0001-7298-6356)
- Robert Musci (ORCID: https://orcid.org/0000-0002-6521-6967)
- Jeroen Geurtsen (ORCID: https://orcid.org/0000-0002-8234-846X)
- Maureen P. Neary (ORCID: https://orcid.org/0000-0002-8584-3677)
- Benjamin Yarnoff (ORCID: https://orcid.org/0000-0002-5147-1588)
- Matthieu Beuvelet (ORCID: https://orcid.org/0000-0001-5450-3613)
- Leonard R. Krilov (ORCID: https://orcid.org/0000-0002-2325-5327)
- Vanessa Gabriel (ORCID: https://orcid.org/0000-0002-2058-5160)
- Ayman Chit
- Maribel Tribaldos
Institutions
- Ithaka Harbors (US)
- Woodbury University (US)
- University of Toronto (CA)
- Cape Fear Community College (US)
- Morristown Medical Center (US)
- Sanofi (France) (FR)
- Sanofi (Netherlands) (NL)
- C3I (United States) (US)
Publication Details
- Journal
- Infectious Diseases and Therapy
- Published
- 2026-02-26
- DOI
- https://doi.org/10.1007/s40121-026-01311-w
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 0.00